2 withdrawn, 1 active not recruiting, 1 completed. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Withdrawn 2, Active not recruiting 1, Completed 1 |
Follow Malignant Neoplasms of Digestive Organs: new trials by email Literature Review of Malignant Neoplasms of Digestive Organs trials Research Report on Malignant Neoplasms of Digestive Organs
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT Pembrolizumab, Clostridium Novyi-NT, Doxycycline - Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs | Phase 1 | Completed | M.D. Anderson Cancer Center | 18 | 2018-07-10 | 2026-11-03 |
| Selumetinib and Olaparib in Solid Tumors Selumetinib, Olaparib - Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 90 | 2017-08-04 | 2026-10-13 |
| Lenvatinib and Capecitabine in Patients With Advanced Malignancies Lenvatinib, Capecitabine - Advanced Cancer, Malignant Neoplasm of Breast | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2016-12-01 | 2017-06-26 | |
| Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies Alisertib, TAK-228 - Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2016-09-01 | 2017-03-27 |
Breast Neoplasms (3) · Urologic Neoplasms (2)
Breast Diseases (3) · Neoplasms (3) · Neoplasms by Site (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Male Urogenital Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Urologic Diseases (2)
AZD 6244 (1) · Capecitabine (1) · Doxycycline (1) · MLN 8237 (1) · lenvatinib (1) · olaparib (1) · pembrolizumab (1) · sapanisertib (1)
M.D. Anderson Cancer Center (4)
United States (2)
David S. Hong, MD (1) · Sarina Piha-Paul, MD (1) · Sarina Piha-Paul, MD, PHD (1) · Shannon Westin, MD (1) · Siqing Fu, MD, PHD (1)